Table 1.

Baseline characteristics

Baseline characteristics
Dose cohort1 mg (n = 10)2 mg (n = 3)4 mg (n = 3)8 mg (n = 13)All (n = 29)
Age (y)
 Mean (range)56.9 (22–69)56 (50–67)61 (50–80)62.7 (34–84)59.8 (22–84)
Sex
 Female4 (40%)2 (66.7%)1 (33.3%)6 (46.2%)13 (44.8%)
 Male6 (60%)1 (33.3%)2 (66.7%)7 (53.9%)16 (55.2%)
ECOG PS at screening
 06 (60%)3 (100%)3 (100%)11 (84.6%)23 (79.3%)
 143 (40%)002 (15.4%)6 (20.7%)
Disease type
 Cutaneous B cell0001 (7.7%)1 (3.5%)
 Follicular8 (80%)3 (100%)2 (66.7%)8 (61.5%)21 (72.4%)
 Marginal1 (10%)003 (23.1%)4 (13.8%)
 SLL/CLL1 (10%)01 (33.3%)1 (7.7%)3 (10.3%)
Stage
 I00000
 II1 (10%)002 (15.4%)3 (10.3%)
 III3 (30%)01 (33.3%)2 (15.4%)6 (20.6%)
 IV6 (60%)3 (100%)2 (66.7%)9 (69.2%)20 (69%)
Grade (follicular only)
 N832821
 103 (100%)1 (50%)6 (46.2%)9 (42.9%)
 26 (75%)01 (50%)2 (15.4%)9 (42.9%)
 3A2 (25%)0002 (9.5%)
FLIPI score (follicular only)
n832821
 00001 (12.5%)1 (4.8%)
 12 (25%)001 (12.5%)3 (14.3%)
 24 (50%)3 (100%)1 (50%)3 (37.5%)11 (52.4%)
 32 (25%)01 (50%)3 (37.5%)6 (28.6%)
  • Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; FLIPI, Follicular Lymphoma International Prognostic Index.